z-logo
open-access-imgOpen Access
Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy
Author(s) -
María Dolores Sánchez-Niño,
Ana B. Sanz,
Susana Carrasco,
Moin A. Saleem,
Peter W. Mathieson,
José Manuel Valdivielso,
Marta RuizOrtega,
J. Egido,
Alberto Ortíz
Publication year - 2010
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfq306
Subject(s) - podocyte , fabry disease , endocrinology , medicine , calcitriol receptor , diabetic nephropathy , nephropathy , kidney , vitamin d and neurology , diabetes mellitus , proteinuria , disease
Transforming growth factor-β1 (TGF-β1) and the macrophage inhibitory factor receptor CD74 link the metabolic disorder with tissue injury in diabetic nephropathy. Fabry disease is an X-linked lysosomal glycosphingolipid storage disorder resulting from a deficient activity of α-galactosidase A that leads to proteinuric renal injury. However, the link between the metabolic abnormality and renal injury is poorly characterized. Globotriaosylsphingosine (lyso-Gb3) was recently identified as a bioactive molecule accumulating in Fabry disease. We hypothesized that lyso-Gb3 could modulate the release of secondary mediators of injury in glomerular podocytes and that recently described nephroprotective actions of vitamin D receptor activation in diabetic nephropathy may apply to lyso-Gb3.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom